Abstract: The present invention is an organic compound (oxime) used to combat chemicals causing poisoning of a nervous system of a human by inhibiting an enzyme in the nervous system leading to an accumulation of acetylcholine, a neurotransmitter, and overstimulation of the nervous system, leading to symptoms such as muscle twitching, convulsions, and respiratory failure, said organic compound comprising (NE)-N-[1-(benzenesulfonyl)quinolin-2-ylidene]hydroxylamine (O?S(?O)(c1ccccc1)n1/c(?N/O)ccc2ccccc21).

Abstract: The present invention relates to a composition comprising nitroxoline, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a plexiform neurofibroma.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.

Abstract: This disclosure provides compounds containing 4-(aminomethyl)-6-(1-methyl-1H-pyrazol-4-yl) isoquinolin-1 (2H)-onestructure, the use thereof for selectively inhibiting the activity of PRMT5 in cooperative with MTA in tumors bearing MTAPDEL mutation, and pharmaceutical compositions comprising the compounds as treatment of various diseases including cancer.

Abstract: The present invention provides novel use of apomorphine for the prevention or treatment of necroptosis-related diseases. The present invention relates to a pharmaceutical composition for the prevention or treatment of necroptosis-related disease, comprising: apomorphine or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

Abstract: This disclosure provides crystalline forms of N-((1R,3S)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide. N ((1R,3S)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide hydrochloride, and N-((1R,3S)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide hydrobromide, pharmaceutical compositions comprising these crystalline forms, methods of making these crystalline forms, and methods of treating a disease, condition, or disorder in a subject comprising administering these crystalline forms to the subject.

Abstract: Compounds as inhibitors of Bcl-2-associated x-protein (BAX) and pharmaceutical compositions thereof are disclosed. Also disclosed are methods of using these compounds for preserving a tissue or treating a disease or disorder in which it is desirable to inhibit BAX.

Abstract: Disclosed herein are methods of treating cancer, said methods comprising administering a therapeutically effective amount of erdafitinib to a patient who has been diagnosed with cancer and who harbors at least one fibroblast growth factor receptor (FGFR) fusion selected from FGFR2-CCDC102A, FGFR2-CCDC147, FGFR2-ENOX1, FGFR2-GPHN, FGFR2-LCN10, FGFR2-PDE3A, FGFR2-RANBP2, FGFR3-ENOX1, FGFR3-TMEM247, IGSF3-FGFR1, RHPN2-FGFR1, and RRM2B-FGFR2.

Abstract: Provided herein are methods of treating cancers that express a low level of a urea cycle enzyme with a GCN2 inhibitor. Also provided herein are diagnostic methods comprising detecting a urea cycle enzyme. Kits comprising a GCN2 inhibitor and instructions for detecting a urea cycle enzyme are also provided herein.

Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide.

Abstract: Described herein are methods and pharmaceutical formulations for treating ocular conditions.

Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

Abstract: The present invention relates to combination therapies for treating KRas G12D cancers, In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SOS1 inhibitor and a KRAS G12D inhibitor of Formula (I), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use thereof.

Abstract: The present invention relates to a gonadotropin-releasing hormone antagonist, which has an antagonistic activity against gonadotropin-releasing hormone and can be used for the prevention or treatment of a sex hormone-dependent disease, such as benign prostatic hypertrophy, hysteromyoma, endometriosis, metrofibroma, precocious puberty, amenorrhea, premenstrual syndrome, or dysmenorrhea, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and a pharmaceutical composition comprising the same.

Abstract: The present invention provides use of a PDE4 inhibitor (e.g., compound of Formula (I)) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for reducing uric acid level, preventing an increased uric acid level in an individual, and treating, preventing, or alleviating a disease, disorder, or condition (for example, gout, hyperuricemia) associated with an increased uric acid level in an individual.

Abstract: The disclosure relates to a particulate composition comprising ensifentrine, wherein the particulate composition further comprises: from greater than 0.00 wt % to 0.60 wt % of 1,3-bis(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido [6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (BMIQU) relative to the total weight of ensifentrine; and from 0.00 wt % to 0.50 wt % of a biuret impurity of formula (A) relative to the total weight of ensifentrine. Further disclosed herein are liquid pharmaceutical compositions comprising the particulate composition, and a process for producing the particulate composition are also described.

Abstract: Method, kit, and pharmaceutical compositions using an inhibitor of EGFR signaling for prevention or treatment of hearing loss are described as Dabrafenib is a therapeutic candidate for preventing cisplatin-induced hearing loss. It has a low effective dose of one tenth of the human equivalent dose (3 mg/kg administered twice day), a good toxicity profile, a therapeutic index of at least 25 in the multi-dose cisplatin regimen, protects both female and male mice, reduces hearing loss in two different strains of mice (FVB/NJ and CBA/CaJ), offers protection from weight loss that occurs during cisplatin chemotherapy, and persistence of hearing protection for at least four months after cisplatin treatments.

Abstract: The present disclosure provides the use of an adenosine A2B receptor as a target in drugs for prevention and/or treatment of pruritus and belongs to the technical field of biological pharmaceuticals. Expression of genes encoding major ligand-gated ion channels is detected based on previously reported single-cell RNA sequencing data of mouse dorsal root ganglions (DRGs), and Adora2b is detected to be highly expressed in Neuron_10, suggesting that Adora2b and Adora2b receptor (the adenosine A2B receptor) may be involved in pruritus regulation. Experimental results show that histamine-induced mouse scratching behavior can be effectively prevented by blocking adenosine A2B receptor activity, indicating that the adenosine A2B receptor is involved in histamine-induced pruritus.

Abstract: The present invention relates to a topical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R1 is ethyl or propyl, preferably propyl; R2 is methyl or ethyl, preferably methyl; R3 is ethyl or propyl, preferably propyl; X is N or CH, preferably CH; n is 1 or 2, preferably n=1; as well as to the uses of said topical compositions for the treatment of diseases or disorders mediated by PDE5 activity and/or NO related endothelial dysfunction, preferably of a disease or disorder of the skin mediated by PDE5 activity and/or NO related endothelial dysfunction, in a subject, preferably in a human, and particularly, for the treatment of ischemic skin ulcers, digital ulcers (DU) in systemic sclerosis, diabetic foot ulcer, leg ulcer, ischemic arterial ulcers, livedoid vasculopathy, Martorell hypertensive ischemic leg ulcer, thromboangiititis obliteragans (Buerger's disease), sickle cell leg ulcer, all of the foregoing preferably for wound healing, further preferably for

Abstract: The present invention relates to pharmaceutical combinations comprising a kinase inhibitor and a NOTCH signaling pathway inhibitor and their use in a method for the prevention, delay of progression or treatment of cancer in a subject.

Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

Abstract: Disclosed herein are methods of treating a subject having an autoimmune or inflammatory disease, and formulations associated therewith, comprising administering to the patient a compound of(S)-5-benzyl-N-(7-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide, or a pharmaceutically acceptable salt thereof, wherein the compound or the pharmaceutically acceptable salt is administered at a dose of about 12.5 mg to about 125 mg free base equivalent of said compound per dose.

Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject an effective amount of iloprost on demand or as rescue medication (also referred to as pro re nata, PRN), wherein iloprost is administered to the subject via inhalation using a portable soft mist inhaler. In preferred embodiments, the soft mist inhaler is the Respimat™ or the Medspray™ wet aerosol inhaler. A method of treating a patient suffering from pulmonary hypertension, comprising: (a) providing a portable and pre-filled soft mist inhaler adapted for delivering an effective amount of iloprost; and (b) administering to the patient the effective amount of iloprost by inhalation on an as-needed basis.

Abstract: The disclosure provides a composition comprising (a) one or more isolated bacterial metabolites selected from prednicarbate, N-palmitoyl-D-threonine and 3,3-difluoro-5-alpha-androstan-17-beta-yl-acetate, and (b) a pharmaceutically acceptable carrier, and use of such composition for reducing inflammation and/or treating an inflammatory disorder in a subject in need thereof.

Abstract: In one aspect. the disclosure relates to pregnane neurosteroid analogues of 5?-pregnan-3?-ol-20-one (3?,5?-THP). Also disclosed herein are methods of making the same, pharmaceutical compositions comprising the same, and methods of treating HIV and/or neuroHIV using the same. The pharmaceutical compositions can alleviate at least one symptom associated with HIV and/or neuroHIV and can be used alone or in combination with other HIV therapies including combination antiretroviral therapy (cART).

Abstract: The present invention provides a novel therapeutic agent for treating inflammatory diseases which reduces the pro-inflammatory response and increases M2 macrophages according to the repolarization of macrophages, thereby exhibiting fewer side effects and excellent anti-inflammatory effects even at low doses compared to conventional steroid anti-inflammatory agent.

Abstract: The present invention relates to a composition for preventing or treating virus infection diseases containing taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, inflammatory cells and inflammatory cytokines were found to decrease in the lungs of an influenza virus-infected animal model to which taurodeoxycholic acid or a pharmaceutically acceptable salt thereof was administered as an inflammasome inhibitor, and thus the inflammasome inhibitor containing taurodeoxycholic acid or a pharmaceutically acceptable salt thereof can be used as an active ingredient in the composition for preventing or treating virus infection diseases.

Abstract: The present disclosure provides compositions and formulations comprising botanicals and natural compounds for the promotion of healthy brain aging in adults and for prevention or inhibition of age associated neurodegenerative changes resulting in cognitive, memory and executive dysfunction including modulation of the age related predisposition to mild cognitive impairment, Alzheimer's disease, hormonal and other dementia related conditions. The present disclosure also provides methods of using the compositions and formulations in treating and preventing neurodegenerative changes resulting in cognitive, memory and executive dysfunction.

Abstract: A pharmaceutical composition for preventing and treating diabetes comprises: cannabidiol and/or a pharmaceutically acceptable salt or ester thereof; and one or more hypoglycemic agents. Optionally, the pharmaceutical composition further comprises one or more pharmaceutically acceptable auxiliary materials. The pharmaceutical composition can effectively decrease blood sugar, and significantly mitigate an adverse reaction induced by metformin or sulfonylurea secretagogues.

Abstract: Methods useful for treating X-linked adrenoleukodystrophy are provided.

Abstract: The disclosure provides methods for treating treatment-resistant depression a subject in need thereof comprising administering to the subject two or more doses of psilocybin.

Abstract: The present invention provides for methods for reducing brain injury in or increasing survival of a subject that is suffering or has suffered cardiac arrest. These methods comprise administering an effective amount of a pharmaceutical composition comprising a lysophosphatidylcholine selected from the group consisting of lysophosphatidylcholine (18:1), lysophosphatidylcholine (18:2), lysophosphatidylcholine (22:6), and/or a combination thereof, optionally lysophosphatidylcholine (18:0), and a pharmaceutical carrier to the subject. The present invention further provides for the pharmaceutical compositions employed in these methods.

Abstract: This invention relates to, among other items, treating Alzheimer's disease by administering epetraborole, or a salt, hydrate or solvate thereof, to a patient in need of treatment thereof.

Abstract: Aspects of the disclosure relate to methods of using oligosaccharide compositions as microbiome metabolic therapies for treating inflammatory lung diseases and disorders, such as chronic obstructive pulmonary disease (COPD) and asthma.

Abstract: A composition, comprising: two or more oligosaccharides selected from the group consisting of 2?-fucosyllactose (2?FL), 3-fucosyllactose (3FL), and 3?-sialyllactose (3?SL) is disclosed.

Abstract: Disclosed are methods of treating cystic fibrosis using AmB and a sterol or compositions comprising AmB and a sterol. Also disclosed are methods of increasing the pH of airway surface liquid in a patient having cystic fibrosis using AmB and a sterol; and methods of decreasing the viscosity of airway surface liquid in a patient having cystic fibrosis using AmB and a sterol.

Abstract: In one aspect, the disclosure relates to pharmaceutical compositions comprising 2?-deoxycytidine analogs, oral and other dosage formulations containing the same, and methods of making the same. In another aspect, the disclosure relates to methods of treating hematological disorders and diseases associated with abnormal cell proliferation using the same. In a still further aspect, the disclosure relates to kits comprising 2?-deoxycytidine analogs useful for treating hematological disorders and diseases associated with abnormal cell proliferation. In still another aspect, the disclosure relates to methods for increasing fetal hemoglobin levels in a subject. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Provided herein are methods of treating myelodysplastic syndromes (MDS) in a subject in need thereof. Also provided herein are methods of treating lower-risk MDS and chronic myelomonocytic leukemia (CMML) in a subject in need thereof. Also provided herein are methods of treating lower-risk MDS and chronic myelomonocytic leukemia (CMML) in a subject having a TP53 mutation in need thereof. Such methods include administering to the subject an effective amount of cedazuridine and an effective amount of decitabine, thereby treating the myelodysplastic syndrome. Such methods may increase the subject's survival (e.g., overall median survival) to about 130% to about 400% relative to survival obtained by treatment with a hypomethylating agent alone.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The invention relates generally to tRNA-based effector molecules having a non-naturally occurring modification and methods relating thereto.

Abstract: Disclosed herein are compositions and methods related to megakaryocyte-derived extracellular vesicles derived from human pluripotent stem cells, where the megakaryocyte-derived extracellular vesicles present unique biomarkers.

Abstract: Described herein are RNA sequence (including siRNA, shRNA, and/or mRNA) carrier platforms for rapid and targeted delivery of siRNAs, shRNAs, and/or mRNAs into cytoplasm of tumor cells, to induce a tumor killing effect. Also described herein is are methods of treating cancer using the RNA sequence carrier platforms described herein.

Abstract: Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject.

Abstract: The present invention relates to therapeutic compositions containing hydrogel particles, at least one hyaluronic acid component and at least one pharmaceutically acceptable excipient as well as methods for producing therapeutic compositions and the use thereof for treating arthritis.

Abstract: The present invention relates to a condensation product, obtained or obtainable by reaction of phenol, formaldehyde, sulfuric acid and urea, for use in a method for the treatment or prevention of a condition associated with one or more protease(s) in a subject, a pharmaceutical composition comprising such a condensation product and for such a use, a pharmaceutical set comprising such a composition and for such a use, such pharmaceutical composition and such a pharmaceutical set and the non-therapeutic use of such a condensation product, such a pharmaceutical composition or such a pharmaceutical set as a disinfectant.

Abstract: The present invention relates to xenon gas for use in in vivo methods of sensitizing glioma cells in a subject for radiation therapy, as well as related in vitro methods.

Abstract: An oxygenated material for application to an alkali burn in an ocular region. The oxygenated material includes a supersaturated oxygen emulsion (SSOE) including perfluorodecalin (PFD) homogenized with a phospholipid and an emulsifying wax. The SSOE comprises a viscosity configured to deliver the SSOE to a site of the alkali burn and sustain a partial pressure of oxygen at the site at a level a plurality of times greater than an ambient partial pressure of oxygen for a plurality of hours. A pressurized dispensing canister is configured to house and dispense the SSOE directly on the site.

Abstract: Provided is a pharmaceutical composition with which an adequate constipation treatment success rate is achieved in pediatric constipation patients aged 1 to 5. The pharmaceutical composition is for treating constipation and contains magnesium oxide as an active ingredient, the pharmaceutical composition being characterized in being orally administered twice a day to pediatric patients aged 1 to 5 and having a body weight of 7.5 kg or above, so that the dosage of magnesium oxide administered per day is 25 to 45 mg/kg.

Abstract: Compositions and methods are provided for increasing mitochondrial biogenesis. When mixed in water, the composition with a high electrical potential is a stable, dry crystalline granule containing 20 to 75 weight percent calcium carbonate. 0.1 to 10 weight percent magnesium hydroxide, and 0.5 to 10 weight percent potassium hydroxide. The granules are a crystalline matrix configured to have slow dissolution and dissociation rates when dissolved in water, which causes the solution's electrical potential to increase gradually. The negative electrical potential voltage increase between 150 and 370 mV induces mitochondrial biogenesis. The method disclosed herein includes ingesting 200 to 4,000 mg of the composition daily.

Abstract: Provided are embodiments of high molecular iodine concentration composition and pharmaceutical formulation and quat-I2 composition comprising a) a quaternary amine (quat) composition and b) the high molecular iodine concentration composition, which may be biostatic persistent, biocidal persistent, and have prolonged biocidal activities against microorganisms for hours after administration of the composition or pharmaceutical formulation. Preparation and use of high molecular iodine concentration composition and pharmaceutical formulation and quat-I2 composition and pharmaceutical formulation are also disclosed. Articles comprising high molecular iodine concentration composition or pharmaceutical formulation or quat-I2 composition or pharmaceutical formulation, as well as preparation and use of same are also disclosed.